EU Industrial R&D Investment Scoreboards 2011

The relative number of fast-growing companies (4 out of 12) is much higheramong bigger EU biotech R&D investors (i.e. those represented in the 1400Scoreboard sample, most large companies) than the number found among thesmaller ones (3 out of 52 found in the EU-1000 sample, most SMEs). Thissuggests that, in this sector, fast-growth is not a particular characteristic of thesmaller companies and that, on the contrary, companies that have reached acertain critical size manage to perform better. This evidence reinforces theimportance of increasing the size of the EU biotech companies.Table 17. Fast growing companies in the Biotechnology sub-sector based in the EU(2010 figures).CompanyR&D,€mR&DCAGR3yr, %Sales,€mSalesCAGR3yr, %RD/NetSales,%Profits/Sales,%Capex/sales,%Intercell 79.9 33.8 34.2 -10.6 233.5 -21.9 11.2 408Crucell 54.6 0.9 338.2 37.0 16.1 3.0 15.1 1188MorphoSys 53.0 40.6 87.0 12.0 60.9 13.0 2.7 435Genmab 48.0 -17.4 78.2 3.2 61.4 -46.9 1.7 229Average EU 68.5 11.7 434.0 10.9 15.8 13.2 8.9 1590Source: The 2011EU Industrial R&D Investment Scoreboard.European Commission, JRC/DG RTDEmployees54The 2011 EU Industrial R&D Investment Scoreboard